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ABSTRACT
There is mounting evidence that as the immune system ages, a progressive deterioration in
normal function occurs. Termed immunosenescence, aging impacts both the innate and adap-
tive immune responses. This review discusses the age-related alterations in the innate im-
mune system, with a specific focus on macrophages. The downstream effect of altered mac-




IMMUNOLOGICAL DEFENSES IN VERTEBRATES con-sist of two immunological subsystems: the
innate immune response and the adaptive im-
mune system. These two immune responses
function in a complicated interactive, cross-reg-
ulative, and synergistic fashion to protect the
host against foreign microbial attack, inhibit tu-
mor development, promote wound healing,
and maintain homeostasis in several tissues.
The innate immune system encompasses a col-
lection of host defenses that range from the
non-specific barrier function of epithelia to the
highly selective recognition of pathogens
through the use of germline-encoded receptors.
A common feature of innate immune system
components is a rapid and blunt response to
infection or tissue destruction.1 In contrast, the
adaptive immune system uses somatically re-
arranged antigen receptor genes to create re-
ceptors for virtually any antigen. Although
slower to respond, the adaptive immune sys-
tem is more flexible and specific, and is able to
combat infections that have evolved to evade
the innate immune response. The induction of
the adaptive immune response is dependent
upon the innate immune response, including
cytokine and chemokine secretion by innate
immune cells and antigen presentation by mac-
rophages and dendritic cells (DC). The adap-
tive immune response can differentiate into a
Th1, Th2, or Th17 immune response, which is
defined by their cytokine secretion profile. Th1
immune responses are responsible for cell-me-
diated immunity (cytotoxic T lymphocytes),
while Th2 immune responses are responsible
for humoral immunity (antibody production).2
Th17 is a newly discovered arm of adaptive im-
mune responses involved primarily in autoim-
mune diseases.3 Upon activation of the adap-
tive immune response, the innate immune
response can also be altered. For example, the
secretion of IFN- by Th1 cells can lead to the
further activation of innate immune cells,
whereas the secretion of immunosuppressive
cytokines such as interleukin-10 (IL-10) by reg-
ulatory T cells can downregulate innate im-
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mune responses. This cross-talk between the
innate and adaptive immune responses dem-
onstrates the highly choreographed and regu-
lated interplay of immune responses occurring
in the body. Both immune responses, however,
exhibit a markedly decreased capacity to func-
tion as the host ages. This leads to increased
susceptibility to infectious diseases, neoplasias,
and autoimmune diseases, and reduced re-
sponses to preventative vaccination. These
complex changes to the immune system over
time are collectively called immunosenescence.4
MACROPHAGES
Mononuclear phagocytes are of critical im-
portance for host immune defenses. Monocytes
emigrate from blood vessels in response to anti-
genic stimuli and differentiate in the tissues
into either macrophages or dendritic cells.5
Macrophages are best known for initiating in-
nate immune responses against microbes by
recognition of pathogen-associated molecular
patterns (PAMPs) through pattern-recognition
receptors (PRPs).6 It has been recently iden-
tified that macrophage populations are dis-
tinctly heterogeneous. Macrophage hetero-
geneity arises as macrophages differentiate
from monocyte precursors and is determined
by the genetic background, as well as by spe-
cific tissue-related and immune-related stim-
uli.5,7 More specifically, microbial antigens, tu-
mor products, and cytokines produced by Th1,
Th2, or Th17 effector cells influence the het-
erogeneity and the state of activation of mac-
rophage populations.8,9
Some researchers have broadly subdivided
heterogeneic macrophages into two subpopu-
lations: M1 and M2 macrophages.10,11 Accord-
ing to this classification, M1 macrophages, or
“classically activated macrophages,” are
thought to be induced in a Th1-like cytokine
environment (IFN-, TNF-, GM-CSF) or upon
recognition of PAMPs (LPS, lipoproteins,
dsRNA) and endogenous “danger” signals.12
M1 macrophages typically produce high levels
of IL-12 and IL-23, low levels of IL-10, and are
strong promoters of Th1 immune responses.12
M1 macrophages also exert anti-proliferative
and cytotoxic activities toward tumor and vi-
rally infected cells, resulting partly from their
ability to secrete reactive oxygen species and
proinflammatory cytokines such as IL-, TNF-
, and IL-6.11–13 M1 macrophages are efficient
mediators of resistance against intracellular
parasites and tumors.10
Macrophages classified as M2, or “alterna-
tively activated macrophages,” develop in the
presence of Th2 cytokines such as IL-4 and IL-
13, deactivating cytokines such as IL-10 and
TGF-, immune complexes, hormones, and
apoptotic cells.11,14 M2 macrophages promote
Th2 responses, have reduced levels of inflam-
matory cytokines, are IL-12low and IL-23low,
and secrete copious amounts of anti-inflam-
matory cytokines such as IL-10 and TGF-.12
Accordingly, M2 macrophages exert selective
immunosuppressive functions and inhibit T
cell proliferation.15,16 The presence of M2 mac-
rophages in healthy individuals in the placenta,
lungs, and immune privileged sites, as well as
in chronic inflammatory diseases like rheuma-
toid arthritis, suggests that M2 macrophages
protect organs and surrounding tissues against
detrimental immune responses. M2 macro-
phages orchestrate encapsulation and contain-
ment of parasites, promote tissue repair, and
enhance tumor progression.10
Although macrophages have been classified
as having an M1 and M2 phenotype, macro-
phages are highly plastic and the tissue mi-
croenvironment can continuously modify their
function.17 It is also thought that condensing
the heterogeneity of macrophage populations
into two subdivisions may be an oversimplifi-
cation. Gordon et al. have stated that this dual
classification “obscures important differences
in macrophage responses.”14 Also, gene array
analyses have shown that treatment of macro-
phages with different cytokines results in
unique functional profiles with remarkably
small overlap.18 We therefore refrain from clas-
sifying macrophages as M1 or M2 for the re-
mainder of this review and focus more on mac-
rophage function as a means of classifying
them.
Macrophages and angiogenesis
One of the earliest physiological responses to
tissue injury or infection is an increase in vas-
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cular permeability and blood flow to the af-
fected area. This is initiated by regional vaso-
dilation and enhanced angiogenesis to facilitate
wound healing. This increase in blood flow and
angiogenesis is largely achieved by factors pro-
duced by cells of the innate immune system,
primarily macrophages. Inflammatory prod-
ucts such as LPS bind to toll-like receptors
(TLR) on macrophages, resulting in the syn-
thesis and release of vascular endothelial
growth factor (VEGF). This results in vasodila-
tion, recruitment of CD31 endothelial pro-
genitor cells, and angiogenesis.19,20 Also, the re-
lease of TNF- and IL-1 by macrophages
promotes blood vessel permeability and an-
giogenesis.21 In addition to inducing angio-
genesis, macrophages have been shown to play
a central role in the remodeling of small con-
duit blood vessels into larger muscular arteri-
oles.22 Tissue-macrophage release of matrix
metalloproteinases also appears to be required
for the extracellular matrix remodeling essen-
tial for effective angiogenesis to occur.23 CCR2-
deficient mice, which lack the necessary
chemokine receptor needed for macrophage
migration, have impaired blood vessel forma-
tion following experimental arterial occlusion.24
However, the formation of blood vessels is
not always beneficial as angiogenesis in some
cases can actually exacerbate a pre-existing dis-
ease phenotype. Within tumors, increased an-
giogenesis leads to accelerated tumor growth,
invasiveness, and metastasis. The role of tu-
mor-associated macrophages (TAM) being ei-
ther pro-angiogenic or anti-angiogenic seems
to depend on their polarization state, which is
influenced by cytokines present in the tissue
milieu.11,25,26 In the majority of cases, the tumor
microenvironment seems to polarize macro-
phages towards a pro-angiogenic phenotype,
resulting in TAMs to be associated with a “bad”
prognosis in most tumor models.27,28 Therapies
that target TAMs have been shown to be ben-
eficial for reduction of tumor size and/or tu-
mor rejection.29 However, not all TAMs sup-
port the growth of tumors, as there are multiple
accounts of macrophages being tumoricidal
and necessary for tumor rejection.30–32 This
again underscores the heterogeneity of macro-
phage populations and their influence on tu-
mor growth or progression. 
Unbridled angiogenesis also plays a role in
the progression of diseases of aging. The pro-
angiogenic cytokine VEGF, which is released
by macrophages, is likely to play a role in the
pathophysiology of arthritis, as mice with a tar-
get disruption of VEGF exhibited significantly
less joint swelling and inflammation than wild-
type animals.33 Also, macrophages have been
implicated to promote abnormal blood vessel
growth in murine tissue injury models.34 In
atherosclerosis, macrophages have been impli-
cated in stimulating angiogenesis in athero-
sclerotic plaques, further promoting inflamma-
tion and exacerbating disease.35
Effect of aging on macrophages
The effect of aging on the innate immune sys-
tem seems to have a detrimental effect on the
health of elderly individuals. There is a signif-
icant decline in the ability to resist infectious
diseases and generate robust protective im-
mune responses in the elderly. Morbidity due
to infectious diseases is high in this segment of
the population. There is a high incidence of in-
fection with viral influenza, respiratory syncy-
tial virus, and pneumococcal pneumonia in el-
derly individuals.36,37 Older individuals also
have an increased incidence of bacterial infec-
tions in the lungs, urinary tract, and skin. The
increased incidence of infections suggests pos-
sible defects in the ability of the innate immune
system to function normally as age increases.
Advanced age is associated with a breakdown
of the epithelial barriers of the skin, lung, and
gastrointestinal tract, enabling the invasion of
delicate mucosal tissues by pathogenic organ-
isms. Also, aging seems to effect the normal
function of cells of the innate immune system,
including macrophages.
The effect of age on macrophages appears to
be multifaceted, affecting almost every aspect of
their normal cellular function. Macrophages
from old mice failed to lyse tumor targets and
produce nitric oxide at levels similar to young
mice.38 Also, Ding et al. found that macrophages
from old mice produced 50% less hydrogen per-
oxide and nitric oxide than young mice when
stimulated with a variety of agents, and that
macrophages from old mice were less respon-
sive to IFN- even though surface expression of
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IFN- receptor was similar in old and young
mice.39 This decrease in IFN- signaling is indi-
cated by reduced phosphorylation of mitogen-
activated protein kinase (MAPK) and signal
transducer and activator of transcription-1
(STAT-1) in aged rodents.39,40 The effect of ag-
ing on macrophages is not restricted to mice, as
human monocytes from aged individuals are re-
ported to display decreased cytotoxicity against
tumor cells in vitro after LPS stimulation, corre-
sponding with decreased release of reactive oxy-
gen and nitrogen intermediates.41,42
Macrophages may also actively contribute to
dysregulated immune function by their secre-
tion of immunosuppressive substances, partic-
ularly prostaglandins (PGE). Macrophages
from old mice have higher PGE2 production
than those from young mice.43 This can affect
multiple cells of the immune system. PGE2 can
inhibit the function of DCs, the primary pro-
fessional antigen presenting cell.44 Also, PGE2
directly inhibits T cells,43 and T cells from the
elderly may be more susceptible to such inhi-
bition than T cells from the young.45 PGE2 also
suppresses IL-12 secretion, decreases surface
expression of MHC class II molecules on APCs,
and enhances IL-10 secretion, resulting in
downregulation of T cell function.46
Other functions of macrophages that are af-
fected by age include antigen presentation and
phagocytosis. It has been reported that antigen-
pulsed macrophages from old mice stimulated
lower levels of T cell proliferation than macro-
phages from young mice.47,48 This may be due
to decreased expression of MHC class II levels
on aged macrophages,49 which contrasts to the
stable expression of MHC class II on young and
old DCs.50 Phagocytosis and clearance of in-
fectious organisms are reduced with advanced
age.51–53 This may be due to the inability of
aged macrophages to recognize invading
pathogens, as aging macrophages demonstrate
decreased expression of TLRs.54 Alternatively,
aging macrophages may not be able to migrate
to the site of infections, as macrophage chemo-
tactic response to complement-derived factors
is impaired in the elderly.55,56
Although the dysfunction of macrophages
may lead to increased susceptibility to microbial
infection, the continuing normal pro-inflamma-
tory function of macrophages over time may
also lead to disease in the elderly. It has been
suggested that the production of pro-inflamma-
tory cytokines by macrophages and fibroblasts
is responsible for many age-associated diseases,
including diabetes, osteoporosis, and athero-
sclerosis.57,58 Termed inflamm-aging, it has been
hypothesized that, as a result of constant anti-
genic stimulation, the continual production of
inflammatory mediators could potentially trig-
ger the onset of inflammatory diseases. This is
exemplified by elevated circulating levels of pro-
inflammatory mediators, including IL-6, IL-1,
TNF-, and PGE2.59 Therefore, when it comes to
macrophage function in the elderly, a happy
medium is desirable for maintaining homeosta-
sis. Too little macrophage activity leads to the
susceptibility of infection from microbial patho-
gens. Too much macrophage activity leads to a
pro-inflammatory state and an induction of au-
toimmune disease. Luckily, the plasticity of
macrophages allows their state of activity to be
virtually reversed.
The effect of age-associated factors on mac-
rophage function is unknown and may be nu-
merous. However, the plasticity of macro-
phages allows them to be a potential target for
therapy to reverse their phenotype and pro-
mote homeostasis.17 Oxidative stress is hy-
pothesized to alter macrophage transcription
factors and nuclear receptors, altering their
ability to respond to inflammatory stimuli.60
Anti-oxidants may be a potential treatment 
to reverse this cause of macrophage dysfunc-
tion, as they seem to improve macrophage in-
flammatory function.61,62 Also, neuroendocrine
factors and stress hormones have also been hy-
pothesized to contribute to the immunosenes-
cence and decreased macrophage function.63
An approach to promote normal macrophage
function in aged hosts may be to take a page
from cancer therapy, and target macrophages
with cytokines to promote the desired macro-
phage function.29 In addition to affecting mac-
rophage function and activation, aging seems
to also affect macrophage polarization.64 The
plasticity of macrophages allows them to
switch their phenotype, and cytokines may be
the key to achieving a reversal of polarization.
Aging macrophages and ocular angiogenesis
Although there has been much work show-
ing how age affects macrophage function
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against microbial pathogens and tumors, little
has been done to show that age affects macro-
phage influence on ocular angiogenesis. Im-
mune vascular interactions can play an impor-
tant role in regulating angiogenesis during
diseases of aging, such as neoplasias, arthritis,
and blinding eye disease.6,65,66 Our laboratory
has investigated the key role of macrophages
in inhibiting the growth of abnormal blood ves-
sels in the eye in age-related macular degener-
ation (AMD), the leading cause of blindness in
people over 50 years of age.66,67 Blindness in
AMD occurs largely from the “wet” form of the
disease that is characterized by the develop-
ment of abnormal blood vessels underneath 
the retina, termed choroidal neovascularization
(CNV).68 We have demonstrated that mice that
lack IL-10 are significantly impaired in their
ability to generate CNV after laser-induced tis-
sue injury to the eye.66 IL-10 inhibits macro-
phages from migrating to the site of tissue in-
jury, implicating that macrophages are serving
in an anti-angiogenic manner in CNV.
Age may impact the polarization of macro-
phages towards an M1 or M2 phenotype. Po-
larization plays a pivotal role in determining
the effector function of macrophages.26 Macro-
phages stimulated in the presence of IFN-,
LPS, or GM-CSF produce high levels of cyto-
kines such as IL-12, IL-23, IL-6, and TNF-,
with low levels of IL-10. This cytokine signa-
ture indicates an anti-angiogenic macrophage,
which also contributes to antibacterial and in-
flammatory immune functions. GM-CSF cul-
tured macrophages inhibit CNV upon injection
into the eyes of mice at the time of tissue in-
jury.66 In the presence of IL-10, IL-4, or IL-13,
macrophages become polarized to a pro-an-
giogenic phenotype, with a cytokine signature
of high levels of IL-10 and low levels of pro-in-
flammatory cytokines such as IL-6 and TNF-.
Interestingly, IL-10 production is elevated in
macrophages from aged rodents and hu-
mans.69,70 This suggests that as a macrophages
age, their polarization may shift from an anti-an-
giogenic, pro-inflammatory phenotype to a pro-
angiogenic, anti-inflammatory phenotype. Also,
this suggests that one of the most important me-
diators of this phenotypic switch is IL-10.
As stated before, our laboratory has shown
that mice that lack IL-10 are significantly im-
paired in their ability to generate CNV after
laser-induced tissue injury to the eye. This
work contrasts with the pro-angiogenic mac-
rophage function that has been described in
other CNV studies. Espinosa-Heidmann et al.
and Sakurai et al. have shown that clodronate-
liposome depletion of macrophages led to less
CNV.34,71 However, the work of Espinosa-Hei-
dmann and colleagues involved the depletion
of macrophages from old mice (16 months of
age). If macrophages from old mice (old mac-
rophages) are skewed towards a pro-angio-
geneic phenotype, then depletion of these mac-
rophages may lead to reduced CNV. Our
hypothesis that macrophages are anti-angio-
genic in the eye is supported by the work of
Lobov et al., who showed that macrophages are
responsible for the induction of apoptosis in the
vascular endothelial cells of the temporary
hyaloid vessels of the developing eye,72 and the
work of Ambati et al., in which mice lacking a
key macrophage recruitment chemokine (CCL-
2) developed spontaneous CNV.73 Taken to-
gether, this evidence suggests that there may
be angiogenic differences in macrophages from
young and old animals.
Additionally, as mentioned above, anti-oxi-
dants reverse the age-associated dysfunction of
macrophages by improving their inflammatory
function.61,62 It has also been found that sup-
plementation of anti-oxidants to patients suf-
fering from AMD delayed the progression of
disease, including the development of CNV.74
This further supports the hypothesis that mac-
rophages function in an anti-angiogenic role in
the eye, and that aging results in macrophage
dysfunction, specifically related to the devel-
opment of ocular blood vessels.
Our laboratory has recently performed ex-
periments to specifically examine the ability of
old macrophages to prevent neovasculariza-
tion.75 In our model of laser-induced CNV, old
mice demonstrated significantly more neovas-
cularization compared to young mice. This in-
creased CNV seems to be due to the failure of
old macrophages to prevent angiogenesis, as
old macrophages injected into the eyes of
young mice did not prevent CNV as effectively
as when macrophages from young mice (young
macrophages) were injected into the eyes of
mice following laser-induced injury. We exam-
ined the cytokine profile of old macrophages in
the eye following laser-induced injury, and we
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observed a significant downregulation of IL-12,
TNF-, and Fas ligand. These cytokines, how-
ever, were unaltered or upregulated in macro-
phages from young mice. Young macrophages
upregulated the proinflammatory cytokines IL-
6 and IL-23, whereas old macrophages did not. 
Again, it seems that IL-10 is the key cytokine
in determining the phenotypic switch of mac-
rophages. Examining the levels of IL-10 in the
eyes of young and old mice, IL-10 levels were
significantly higher in old animals.75 This sug-
gests that the micromilieu in old mice might
create an environment that promotes the po-
larization of infiltrating macrophages to a pro-
angiogenic phenotype. The effect of IL-10 on
macrophage polarization is further exemplified
when we treated young macrophages with IL-
10 and injected them into the eyes of laser-in-
jured eyes; IL-10-treated macrophages failed to
inhibit CNV.75 This clearly highlights IL-10 as
a pro-angiogenic cytokine and that macro-
phages, in the presence of IL-10, do not dem-
onstrate anti-angiogenic properties.
We also demonstrated the effect of aging on
macrophages and their ability to regulate
angiogenesis in vitro. Thioglycollate-induced
peritoneal macrophages were harvested and
assessed for their ability to inhibit the growth
and proliferation of vascular endothelial cells.
Macrophages from young and IL-10 deficient
animals significantly inhibited vascular endo-
thelial cell proliferation, whereas macrophages
from old mice had no effect.75 This demon-
strates a direct inability of senescent macro-
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FIG. 1. The effect of senescence on macrophage cytokine expression and angiogenesis. Macrophages from young
mice demonstrate increased levels of proinflammatory cytokines, including TNF-, IL-23, IL-12, and IL-6. This results
in an anti-angiogenic macrophage phenotype, leading to less choroidal neovascularization (CNV) following laser in-
duced injury. Macrophages from old mice, however, demonstrate decreased levels of the same proinflammatory cy-
tokines and increased levels of the immunosuppresive cytokine IL-10. These macrophages are skewed to an alterna-
tively activated macrophage phenotype, resulting in increased CNV following laser-induced injury.
phages to inhibit the growth of blood vessel
cells. The effect of aging on macrophage po-
larization and angiogenesis is summarized in
Figure 1. 
SUMMARY
Aging results in the dysfunction of both the
innate and adaptive immune systems. Im-
munosenescence leads to increased suscepti-
bility to infection and tumor formation and
inflammatory diseases of aging such as osteo-
porosis and diabetes. Macrophages seem par-
ticularly susceptible to immunosenescence,
and over time seem to polarize towards a pro-
angiogeneic phenotype. This can result in the
formation of unwarranted blood vessels and
exacerbation of disease processes, such as
AMD. Fortunately, the plasticity of macro-
phages renders them ideal targets for therapy,
as cytokine/antibody treatment and gene ther-
apy may result in a reversal of disease pheno-
type. 
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